MBTPS1 and inflammatory bowel disease: However, even we and others could not detect a disease-dependent change in the plasma S1P level; manipulation of the S1P signaling pathway by treating UC patients with ozanimod seems to be a promising approach that several clinical trials are ongoing, investigating S1P modulators in IBD [50].